CRITICAL REVIEW

Capturing seizures in clinical trials of antiseizure medications for KCNQ2-DEE

John J. Millichap1,2 | Cynthia L. Harden3 | Dennis J. Dlugos4 | Jacqueline A. French5 | Noam N. Butterfield3 | Celene Grayson3 | Ernesto Aycardi3 | Simon N. Pimstone3,6

1Epilepsy Center and Division of Neurology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA
2Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
3Xenon Pharmaceuticals, Inc., Burnaby, British Columbia, Canada
4Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
5Department of Neurology NYU Langone School of Medicine, New York, NY, USA
6Division of General Internal Medicine, University of British Columbia, Burnaby, British Columbia, Canada

Correspondence
John J. Millichap, Epilepsy Center and Division of Neurology, Ann & Robert H. Lurie Children’s Hospital of Chicago 225 East Chicago Avenue, Box 29, Chicago, Illinois 60611-2605, USA.
Email: jmillichap@luriechildrens.org

Abstract

Literature review of patients with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) reveals, based on 16 reports including 139 patients, a clinical phenotype that includes age- and disease-specific stereotyped seizures. The typical seizure type of KCNQ2-DEE, focal tonic, starts within 0-5 days of life and is readily captured by video-electroencephalography VEEG for clinical and genetic diagnosis. After initial identification, KCNQ2-DEE seizures are clinically apparent and can be clearly identified without the use of EEG or VEEG. Therefore, we propose that the 2019 recommendations from the International League against Epilepsy (ILAE), the Pediatric Epilepsy Research Consortium (PERC), for capturing and recording seizures for clinical trials (Epilepsia Open, 4, 2019, 537) are suitable for use in KCNQ2-DEE-associated antiseizure medicine (ASM) treatment trials. The ILAE/PERC consensus guidance states that a caregiver-maintained seizure diary, completed by caregivers who are trained to recognize seizures using within-patient historical recordings, accurately captures seizures prospectively in a clinical trial. An alternative approach historically endorsed by the Food and Drug Administration (FDA) compares seizure counts captured on VEEG before and after treatment. A major advantage of the ILAE/PERC strategy is that it expands the numbers of eligible patients who meet inclusion criteria of clinical trials while maintaining accurate seizure counts (Epilepsia Open, 4, 2019, 537). Three recent phase 3 pivotal pediatric trials investigating ASMs to treat syndromic seizures in patients as young as 2 years of age (N Engl J Med, 17, 2017, 699; Lancet, 21, 2020, 2243; Lancet, 17, 2018, 1085); and ongoing phase 2 open-label pediatric clinical trial that includes pediatric epileptic syndromes as young as 1 month of age (Am J Med Genet A, 176, 2018, 773), have already used caregiver-maintained seizure diaries successfully. For determining the outcome of a KCNQ2-DEE ASM treatment trial, the use of a seizure diary to count seizures by trained observers is feasible because the seizures of KCNQ2-DEE...
1 | POSITION

The purpose of this paper is to provide justification for using a caregiver-maintained seizure diary, informed by VEEG training, to capture seizure frequency as the primary outcome in KCNQ2-DEE ASM clinical trials. The approach proposed herein follows from the recommendation published in 2019 by the regulatory task force and the pediatric commission of the ILAE, in collaboration with PERC.1 We propose that historical VEEG be used to confirm seizures is feasible in KCNQ2-DEE. These recordings would then be used to train caregivers to identify the seizures, enabling them to maintain a seizure diary throughout the clinical trial. For consistency, all efforts would be made to the limit the number of caregiver recording seizures into the diary during the clinical trial.

2 | BACKGROUND

2.1 | VEEG is appropriate for primary assessment of seizures in a subset of neonates who have very frequent seizures of heterogeneous etiologies

VEEG has been considered by the Food and Drug Administration (FDA) to be the preferred method to measure seizure frequency in circumstances where seizure counting by observation is problematic. VEEG has been used as a primary outcome measure in ASM trials in infants and young children, from 1 month to 4 years of age.2-7 The rationale is that some types of seizures in young children may be difficult to distinguish from other nonepileptic movements, making seizure classification and counting difficult. Counting by clinical observation alone could lead to observers counting nonseizure movements as seizures and/or undercounting real seizures. To address these difficulties, the Agency has recommended the use of video-EEG with correlation of seizures with EEG electrical activity for study of infants and neonates. For treatment trials that include infants,2-7 video-EEG has often been performed for 48 to 72 hours before treatment with review by several expert reviewers to achieve consensus on the seizure types and frequency. Following treatment with an ASM, another video-EEG over the same time frame is performed and the seizure counts compared to pretreatment observations to determine the primary endpoint of seizure reduction. While treatment trials are less common in the neonatal period, evaluating seizures in neonates presents similar challenges. Evaluating a treatment by counting seizures captured on video-EEG both before and after treatment is clearly necessary for evaluating seizures of neonates wherein the etiology is often hypoxic-ischemic encephalopathy or structural/metabolic, resulting in seizure types that are varied, may be subtle and difficult to identify, and therefore difficult to count without the use of video-EEG.8,9 Further, seizures in children outside the neonatal period are usually clinically apparent, mitigating the need for video-EEG to inform an accurate seizure count.

2.2 | Seizures in KCNQ2-DEE

A literature search of PubMed was undertaken using the key words KCNQ2 encephalopathy, KCNQ2 developmental encephalopathy, KCNQ2 seizures, KCNQ2 developmental and epileptic encephalopathy, KCNQ2 epileptic encephalopathy, KCNQ2-EEG and KCNQ2-DEE. Reports from 2012 and on were included as the disease was first described and characterized in 2012 although unrecognized cases were likely described prior to this. Abstracts were not included. Reports with seizure descriptions were included. Literature review of 16 case studies of patients diagnosed with the genetic syndrome of KCNQ2-DEE reveals that the associated seizures are characterized primarily by motor seizure types, focal
Tonic seizures being the most common, which are present at onset and persist beyond the neonatal period (see Table 1). Tonic-clonic and myoclonic seizures are also described. Many seizure descriptions include apnea as a prominent associated feature of the tonic seizure. Other seizure descriptions include generalized tonic-clonic, generalized tonic, focal motor, myoclonic, and epileptic spasms, which are all clinically apparent motor seizure phenomena. Overall, out of 137 KCNQ2-DEE patients reported in the 16 cited studies, 94% (129 patients) had clear motor seizures (excluding patients with myoclonic events only; see explanation to follow), with the majority of patients having focal tonic seizures (81%, n = 111). In fact, focal tonic seizures were the main seizure type in most, if not all, of the patients described in the cited studies (see Table 1).

A focal tonic seizure is an electro-clinical seizure type that is readily observed and associated with a clear EEG correlate of contralateral amplitude suppression at the outset. A description of the characteristic seizures and EEG findings in a 6-week-old boy with KCNQ2-DEE is as follows, reported by Serino et al19: “Seizure semiology was characterized by unilateral eye and head deviation, upper limb hypertonus sometimes followed by asynchronous and asymmetrical clonic jerks, eyelid myoclonias, and polypnoea. Ictal EEG was characterized by focal, low-voltage, fast activity, followed by recruiting theta rhythms and bilateral, focal, spike-wave complexes, alternatively localized to one hemisphere and subsequently diffusing to the other.”

Notably, there were no reports of electrographic subclinical seizures in the KCNQ2-DEE cases reviewed. Multifocal epileptiform features were frequently described as part of the EEG background, as was an intermittent non-seizure–associated burst-suppression pattern often present until 6 months of age. A minority of patients with KCNQ2-DEE also suffer bouts of epileptic spasms within the first year of life.

In summary, the characteristic seizures of KCNQ2-DEE are clear countable motor events that can be readily clinically observed. The majority are focal tonic, along with other motor seizure types including generalized tonic, clonic, and generalized tonic-clonic seizures. One exception is myoclonic seizures. Single myoclonic jerks may be nonepileptic and are very hard to count. In many trials, myoclonic jerks are not considered a countable seizure and are not included in the efficacy endpoint. Repeated myoclonic movements are counted as clonic seizures. Finally, it is clear that KCNQ2-DEE affected infants do not have highly variable seizure types or subtle subclinical seizures.

| Author/Year | Patients (n) | Motor seizuresa (Patients, n) | Total focal tonic (Patients, n) |
|-------------|-------------|------------------------------|-------------------------------|
| Duan et al (2018)8 | 1 | 1 | 1 |
| Hortiguela et al (2017)9 | 13 | 13 | 9 |
| Kato et al (2013)10 | 12 | 11 | 11 |
| Ko et al (2018)11 | 7 | 7 | 7 |
| Lee et al (2019)12 | 7 | 7 | 7 |
| Milh et al (2013)13 | 16 | 14 | 12 |
| Millichap et al (2016)14 | 23 | 19 | 15 |
| Numis et al (2014)15 | 3 | 3 | 3 |
| Olson et al (2017)16 | 10 | 10 | 6 |
| Pisano et al (2015)17 | 15 | 15 | 12 |
| Schubert-Bast et al (2017)18 | 1 | 1 | 1 |
| Serino et al (2013)19 | 1 | 1 | 1 |
| Spagnoli et al (2018)20 | 3 | 2 | 2 |
| Vilan et al (2017)21 | 9 | 9 | 9 |
| Weckhuysen et al (2012)22 | 8 | 8 | 8 |
| Weckhuysen et al (2013)23 | 9 with severe DEE | 9 | 8 |

Total N = 137b 129b/137 (94.2%) 111b/137 (81.0%)

aIncluding focal tonic, generalized tonic, clonic, tonic-clonic, generalized tonic-clonic seizures.

bOne patient (who had focal tonic seizures) was reported in both Millichap 2016 and Olsen 2017. That patient is only counted once; therefore, the totals in each column appear to be one patient less than when patients from all the reports are added together.
3 | RATIONALE SUPPORTING USE OF A CAREGIVER DIARY FOR PRIMARY ASSESSMENT OF SEIZURE FREQUENCY IN KCNQ2-DEE

Given that patients will have had EEG or VEEG confirmation of seizures, which is recommended by the ILAE for the evaluation of children with undiagnosed repeated abnormal events,24 the use of seizure diaries as the primary method to evaluate seizure frequency in the infantile and early childhood KCNQ2-DEE population is supported by the following:

a. The most frequent and typical seizures of KCNQ2-DEE are easily observable, most clinically relevant, and easily counted.
   • Multiple reports describe KCNQ2-DEE seizures as stereotypical, most often focal tonic in semiology, and observable from birth.8–21
   • Parents have the ability to correctly identify seizures with a high degree of confidence (KCNQ2 survey), which can be further improved with training.1

b. Seizure diaries allow frequent, daily recording of seizure burden to measure treatment effects.
   • This is important because there is typically some variability in the timing and frequency of seizures, so daily seizure capture provides the granularity needed to accurately measure treatment effect.
   • The alternative, VEEG, would only allow for 2–3 days of seizure capture after treatment.

c. Caregiver-reported seizure diaries have been successfully employed in other studies of pediatric epilepsy syndromes such as Dravet and Lennox-Gastaut (LGS).
   • For example, in a study of patients with Dravet syndrome, “convulsive seizures” specifically tonic-clonic, tonic, clonic, or atomic were counted toward the primary outcome.25 “Non-convulsive seizures,” defined as myoclonic, countable focal, other focal, or absence seizures, were captured as a secondary outcome.
   • In another study of Dravet syndrome, again “convulsive” seizures were used to assess the primary outcome, which is a clearly observable and dangerous seizure type.26
   • In a study of LGS, “drop seizures” comprised of tonic-clonic, tonic, or atomic seizures that resulted in the patient dropping, informed the primary outcome.27 Total seizures (the sum of all tonic-clonic, tonic, clonic, myoclonic, countable focal, other focal and absence seizures) were counted as part of the study’s secondary outcomes.

d. The ability to use a seizure diary rather than VEEG has many advantages, not the least of which is convenience for the participating families.1

• Subjects in the previously preferred infant trial design were typically required to undergo at least two 24–48 hour VEEGs, most likely as an inpatient, which is burdensome to families. A 24– to 48-hour VEEG study may not capture enough seizures (or any seizures in patients with less frequent than daily seizures) and therefore may not adequately reflect the true seizure burden of the participant. Alternatively, a seizure diary enables enrollment of patients whose seizure frequency is variable, less than daily, or presents in clusters.1

4 | SEIZURE COUNTING IN AN ASM TREATMENT TRIAL IN KCNQ2-DEE

For research purposes, the seizure types used for evaluating the effect of an intervention must be clearly defined. As listed in Table 1,8–23 the seizures seen in KCNQ2-DEE include the following motor seizures: focal tonic (most common), generalized tonic, clonic, and generalized tonic-clonic seizures. These seizure types would be counted in the primary analysis for a study evaluating ASM treatment in KCNQ2-DEE. Important exclusions to countable seizures for KCNQ2-DEE would include single myoclonic jerks or staring spells without a motor component consistent with the seizure types included.

Reports of EEG correlation with clinical seizures support both focal and generalized onset of these seizure types. The EEG background may be chaotic, showing multifocal spikes or burst suppression.21,22 Therefore, each seizure type counted in a clinical trial of ASM treatment for KCNQ2-DEE could be classified as either focal or generalized in onset, as supported by EEG correlation.28

As part of determining eligibility for an ASM clinical trial in KCNQ2-DEE, an adjudication committee consisting of KCNQ2 variant experts would need to vet each potential trial participant prior to enrollment by evaluating phenotype, genotype, and VEEG findings. The adjudication committee would provide an additional review of the VEEG information to ensure that appropriate patients are enrolled.

5 | TRAINING CAREGIVERS ON COUNTING SEIZURES FOR KCNQ2-DEE CLINICAL TRIALS

A systematic training program to teach caregivers how to identify seizures is proposed below.

1. Locate historical VEEG of typical seizures, or repeat VEEG if seizure semiology has changed; review with parents or caregivers to confirm that these are typical seizures.
2. Invite parents or caregivers to review VEEG results at a time when everyone is available for 1 hour and is calm.
3. Choose no more than two persons to be officially trained as seizure-counters.
4. Review seizures to be counted in the study via VEEG.
5. Discuss seizure features with seizure-counters, including:
   a. KCNQ2-DEE seizures include the following motor seizures: focal tonic (most common), generalized tonic, clonic, and generalized tonic-clonic seizures.
   b. Important exclusions to study countable seizures are single myoclonic jerks or staring spells without a motor component consistent with the seizure types included.
6. Play video of myoclonus or other nonseizure events to demonstrate what not to count (within the patient or historical).

6 | CONCLUSIONS

The use of seizure diaries as the primary method to evaluate seizure frequency in the infantile KCNQ2-DEE population is supported by the following rationale. Multiple reports conclude that KCNQ2-DEE seizures are stereotyped and observable from birth. It follows then that seizure diaries are a robust method to capture the true seizure burden of a patient rather than relying on a very small window of time with the use of video-EEG, and there is precedent for this approach in syndromic epilepsies. Moreover, this approach allows a broader range of patients to be eligible to participate in this important trial, such as those with less than daily seizures in whom video-EEG as part of the study protocol becomes impractical. Inclusion of a broader group of patients is also key given the rarity of the disease.

Accordingly, we propose that the primary outcome measure of an ASM treatment trial in KCNQ2-DEE that includes children as young as 1 month of age can be identified and documented by parents in a diary. In a clinical trial setting, an adjudication committee consisting of KCNQ2 variant experts will vet each potential subject for trial enrollment by evaluation of phenotype, genotype, and video-EEG findings. Training on seizure identification using video-EEG would be provided systematically to all potential caregivers of a given subject. The seizures captured and used for training parents will be recorded in a seizure diary.

In addition to being supported by multiple preceding studies in pediatric syndromic epilepsies in the age group included in our trial, our proposal is in alignment with a recently published consensus document from the Regulatory Task Force and the Pediatric Commission of the International League against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). This publication clearly outlines the rational for assessing the outcome of an ASM treatment trial in very young children by using daily outpatient seizure diaries with the seizures to be captured identified by prior EEG, video, and video-EEG. This approach combines the rigor of accurate seizure identification and classification via video-EEG with a clinically relevant seizure diary count by caregivers and is practical, efficient, and generalizable to clinical practice. The consensus statement recommends the following procedure for seizure documentation in an interventional study: “Seizures with clinical signs will be confirmed by video-EEG (preferred) or video (with clear semiology and supporting clinical and interictal EEG data) for each study participant and reviewed centrally by experts in pediatric epilepsy. If available, prior clinically obtained video-EEG or video recordings may be used to confirm that the events in question are seizures if the seizure semiology has remained the same. If no clinically obtained recordings are available, then they will be obtained as study procedure before randomization. The clinically observable focal onset seizures documented by video-EEG or video will be the events of interest for the study’s primary endpoint. In the pretreatment baseline period, titration phase, and maintenance period, the above clinically observable seizures will be recorded in seizure diaries by caregivers.”

ACKNOWLEDGMENTS

This work was supported in part by funding from the Ann & Robert H. Lurie Children’s Hospital of Chicago Precision Medicine Initiative (JJM).

CONFLICTS OF INTEREST

Drs. Grayson, Harden, Butterfield, Pimstone, and Aycardi are employed by Xenon Pharmaceuticals Inc (“Xenon”). They receive salaries and may hold stock or stock options in Xenon. Dr Millichap reports personal fees from American Academy of Neurology, personal fees from Up-To-Date, personal fees from BMJ Best Practice, grants and personal fees from UCB Pharma, grants and personal fees from Mallinckrodt, personal fees from Esai, personal fees from Biomarin, personal fees from Ionis, personal fees from Greenwich, personal fees from Sunovion, personal fees from Upsher-Smith, grants from NIH, grants from Citizens United for Research in Epilepsy, personal fees from Praxis, grants and personal fees from Trumacro, outside the submitted work; Pursuant to a Consulting Agreement between Ann and Robert H. Lurie Children’s Hospital of Chicago and Xenon, it is anticipated that Dr Millichap will serve as the Global Coordinating Investigator for Xenon’s planned Phase 3 study of XEN496. The Ann and Robert H. Lurie Children’s Hospital of Chicago receives financial compensation from Xenon in exchange for Dr Millichap’s services. In addition, Dr Millichap, in a personal capacity, is a consultant for Xenon and also serves as a member
the Xenon Steering Committee for XEN496. Dr Millichap receives financial compensation from Xenon in exchange for his services. Dr French receives NYU salary support from the Epilepsy Foundation and for consulting work and/or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Acadia, Adamas, Adex, Aeonian, Alexa, AnaveX, Arvelle Therapeutics, Inc, Axcella Health, Axovant, Biogen, Biomotiv/Koufiz, Blackfynn, Bloom Science, Bridge Valley Ventures, Cavion, Cerebral Therapeutics, Cerevel, Clinilabs, Concert Pharmaceuticals, Covance, Crossjekt, CuroNz, Eisai, Empatica, Encoded, Engage Therapeutics, Encoded, Epitel, GW Pharma, Idorsia, Impax, Ionis, J&J Pharmaceuticals, Marinus, MonosolRx, Neurelis, Neurocrine, Novartis, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc, Pfizer, Pfizer-Neusentis, Praxis, Redpin, Sage, Sancillio, Shire, SK Life Sciences, Springworks, Stoke, Sunovion, Supernus, Takeda, UCB Inc, Ultragenyx, Upsher-Smith, Vyera, West Therapeutic Development, Xenon, Xeris, Zogenix, and Zynebra. Dr French has also received research grants from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, SK Life Sciences, Sunovion, UCB, and Zogenix as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, and NINDS (#U01-NS038455). She is on the editorial board of Lancet Neurology and Neurology Today. She is scientist officer for the Epilepsy Foundation for which NYU receives salary support. She has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Adamsar, Arvelle Therapeutics, Inc, Axovant, Biogen, Blackfynn, Crossjekt, CuroNz, Eisai, Engage, Idorsia, Neurelis, Novartis, Otsuka, Ovid, Pfizer, Redpin, Sage, SK Life Sciences, Sunovion, Takeda, UCB, Ultragenyx, and Zynebra. Dr Druligos receives salary support from NIH, Commonwealth of Pennsylvania Department of Health, Pediatric Epilepsy Research Foundation, and The Epilepsy Study Consortium. He is an investigator on research grants awarded to CHOP from Zogenix, Greenwich Biosciences, Brain Sentinel, Neurelis, Q-State, Aquestive, Bio-Pharm, SK Life Sciences, and Encoded Therapeutics. He has received travel expenses for protocol development conferences or investigator meetings from Marinus, Ovid/ Takeda, Ultragenyx, Pfizer, Biogen, BioMarin, and Xenon. He received honoraria and/or travel support for CME and other educational programs from Wake Forest University School of Medicine, American Epilepsy Society, American Academy of Neurology, Epilepsy Foundation of America, Epilepsy Foundation of North Carolina, Medscape, Miller Medical Communications, Ecuador Neurology Project, Ministry of Health of the United Arab Emirates, Seoul National University, and the Chinese Pediatric Society.

**ETHICAL PUBLICATION STATEMENT**

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

**ORCID**

*John J. Millichap* [ORCID: 0000-0002-0798-0131]
*Jacqueline A. French* [ORCID: 0000-0003-2242-8027]

**REFERENCES**

1. Auvin S, French J, Dlugos D, Knupp KG, Perucca E, Arzimanoglou A, et al. Novel study design to assess the efficacy and tolerability of antiseizure medications for focal-onset seizures in infants and young children: A consensus document from the regulatory task force and the pediatric commission of the International League Against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). Epilepsia Open. 2019;4:537–43.

2. Neurontin [package insert]. New York, NY: Parke-Davis Division of Pfizer, Inc., New York, NY; 2009.

3. ClinicalTrials.gov. A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures. ClinicalTrials.gov identifier: NCT02072824. 2014 [updated on October 9, 2018]. Available from: clinicaltrials.gov/ct2/show/NCT02072824

4. Novotny E, Renfroe B, Yardi N, Nordli D, Ness S, Wang S, et al. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology. 2010;74:714–20.

5. Piña-Garza JE, Espinoza R, Nordli D, Bennett DA, Spirito S, Stites TE, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology. 2005;65:1370–5.

6. Pina-Garza JE, Levisohn P, Guçuyener K, Mikati MA, Warnock CR, Conklin HS, et al. Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology. 2008;70:2099–108.

7. Pina-Garza JE, Nordli DR Jr, Rating D, Yang H, Schiemann-Delgado J, Duncan B, et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009;50:1141–9.

8. Duan H, Peng J, Kessi M, Yin F. De novo KCNQ2 mutation in one case of epilepsy of infancy with migrating focal seizures that evolved to infantile spasms. Child Neurol Open. 2018;5:2329048X18767738.

9. Hortiguela M, Fernandez-Marmiesse A, Cantarín V, Gouveia S, García-Penas JJ, Fons C, et al. Clinical and genetic features of 13 Spanish patients with KCNQ2 mutations. J Hum Genet. 2017;62:185–9.

10. Kato M, Yamagata T, Kubota M, Arai H, Yamashita S, Nakagawa T, et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia. 2013;54:1282–7.

11. Ko A, Youn SE, Kim SH, Lee JS, Kim S, Choi JR, et al. Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy. Epilepsy Res. 2018;141:48–55.

12. Lee JC, Chang TM, Liang JS, Li SY. KCNQ2 mutations in childhood nonlesional epilepsy: variable phenotypes and a novel mutation in a case series. Mol Genet Genomic Med. 2019;7:e00816.

13. Milh M, Boutry-Kryza N, Suter-Sardo J, Mignot C, Auvin S, Lacoste C, et al. Similar early characteristics but variable
neurological outcome of patients with a de novo mutation of KCNQ2. Orphanet J Rare Dis. 2013;8:80.

14. Millichap JJ, Park KL, Tsuchida T, Ben-Zeev B, Carmant L, Flamini R, et al. KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet. 2016;2:e96.

15. Numis AL, Angriman M, Sullivan JE, Lewis AJ, Striano P, Nabbout R, et al. KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. Neurology. 2014;82:368–70.

16. Olson HE, Kelly M, LaCoursiere CM, Pinsky R, Tambunan D, Shain C, et al. Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression. Ann Neurol. 2017;81:419–29.

17. Pisano T, Numis AL, Heavin SB, Weckhuysen S, Angriman M, Suls A, et al. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia. 2015;56:685–91.

18. Schubert-Bast S, Hofstetter P, Fischer D, Schloesser R, Ramantani G, Kieslich M. Sodium channel blockers in KCNQ2-encephalopathy: Lacosamide as a new treatment option. Seizure. 2017;51:171–3.

19. Serino D, Specchio N, Pontrelli G, Vigevano F, Fusco L. Video/EEG findings in a KCNQ2 epileptic encephalopathy: a case report and revision of literature data. Epileptic Disord. 2013;15:158–65.

20. Spagnoli C, Salerno GG, Iodice A, Frattini D, Pisani F, Fusco C. KCNQ2 encephalopathy: a case due to a de novo deletion. Brain Dev. 2018;40:65–8.

21. Vilan A, Mendes Ribeiro J, Striano P, Weckhuysen S, Weeke LC, Brilstra E, et al. A distinctive ictal amplitude-integrated electroencephalography pattern in newborns with neonatal epilepsy associated with KCNQ2 mutations. Neonatology. 2017;112:387–93.

22. Weckhuysen S, Mandelstam S, Suls A, Audenaert D, Deconinck T, Claes LR, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol. 2012;71:15–25.

23. Weckhuysen S, Ivanovic V, Hendrickx R, Van Coster R, Hjalgrim H, Moller RS, et al. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology. 2013;81:1697–703.

24. Wilmshurst JM, Gaillard WD, Vinayan KP, Tsuchida TN, Plouin P, Van Bogaert P, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia. 2015;56:1185–97.

25. Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;377:699–700.

26. Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2020;394:2243–54.

27. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–96.

28. Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58:531–42.

How to cite this article: Millichap JJ, Harden CL, Dlugos DJ, et al. Capturing seizures in clinical trials of antiseizure medications for KCNQ2-DEE. Epilepsia Open. 2021;6:38–44. https://doi.org/10.1002/epi4.12466